Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort
Copyright © 2021 Elsevier Inc. All rights reserved..
INTRODUCTION/BACKGROUND: The USPSTF (United States Preventive Services Task Force) guidelines suggest criteria centering on smoking status and age to select patients for lung cancer screening. Despite the significant advances in screening with low-dose computed tomography (LDCT), cancer detection rate is low (1.1%), highlighting the need to investigate possible ways to refine the current lung cancer screening strategy. Our aim was to determine clinical risk factors predictive of lung cancer in an urban safety-net hospital.
MATERIALS AND METHODS: We performed a retrospective chart review of 2847 patients who received LDCT screening for lung cancer between 3/1/2015 and 12/31/2019. Patient demographics and medical history were collected. A bivariate logistic regression was used to evaluate predictors of lung cancer.
RESULTS: Compared to the National Lung Cancer Screening Trial (NLST) population, our screening cohort had significantly more African Americans (38.2% vs. 4.5%, P < .0001), more obesity (32.7% vs. 28.3%, P < .0001), and higher rates of chronic obstructive pulmonary disease (COPD) (45.9% vs. 5.0%, P < .0001). The strongest predictors of lung cancer were COPD (odds ratio [OR] = 2.14, P < .0001) and a family history of lung cancer (OR = 2.77, P < .0001). Age (OR = 1.04, P< .001) and pack years (OR = 1.01, P< .001) were less predictive.
CONCLUSION: A diagnosis of COPD and family history of lung cancer were most predictive of lung cancer in a screening cohort at our urban safety-net hospital. Future studies should focus on whether inclusion of these additional risk-factors improves proportion of lung cancer detected via screening.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical lung cancer - 23(2022), 2 vom: 25. März, Seite e165-e170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Sarah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic obstructive pulmonary disease |
|---|
| Anmerkungen: |
Date Completed 17.03.2022 Date Revised 02.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cllc.2021.07.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329367986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329367986 | ||
| 003 | DE-627 | ||
| 005 | 20231225204949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cllc.2021.07.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329367986 | ||
| 035 | |a (NLM)34393063 | ||
| 035 | |a (PII)S1525-7304(21)00190-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Sarah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2022 | ||
| 500 | |a Date Revised 02.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION/BACKGROUND: The USPSTF (United States Preventive Services Task Force) guidelines suggest criteria centering on smoking status and age to select patients for lung cancer screening. Despite the significant advances in screening with low-dose computed tomography (LDCT), cancer detection rate is low (1.1%), highlighting the need to investigate possible ways to refine the current lung cancer screening strategy. Our aim was to determine clinical risk factors predictive of lung cancer in an urban safety-net hospital | ||
| 520 | |a MATERIALS AND METHODS: We performed a retrospective chart review of 2847 patients who received LDCT screening for lung cancer between 3/1/2015 and 12/31/2019. Patient demographics and medical history were collected. A bivariate logistic regression was used to evaluate predictors of lung cancer | ||
| 520 | |a RESULTS: Compared to the National Lung Cancer Screening Trial (NLST) population, our screening cohort had significantly more African Americans (38.2% vs. 4.5%, P < .0001), more obesity (32.7% vs. 28.3%, P < .0001), and higher rates of chronic obstructive pulmonary disease (COPD) (45.9% vs. 5.0%, P < .0001). The strongest predictors of lung cancer were COPD (odds ratio [OR] = 2.14, P < .0001) and a family history of lung cancer (OR = 2.77, P < .0001). Age (OR = 1.04, P< .001) and pack years (OR = 1.01, P< .001) were less predictive | ||
| 520 | |a CONCLUSION: A diagnosis of COPD and family history of lung cancer were most predictive of lung cancer in a screening cohort at our urban safety-net hospital. Future studies should focus on whether inclusion of these additional risk-factors improves proportion of lung cancer detected via screening | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Chronic obstructive pulmonary disease | |
| 650 | 4 | |a Disparities | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Risk-model | |
| 700 | 1 | |a Pavesi, Flaminio |e verfasserin |4 aut | |
| 700 | 1 | |a Steiling, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Asokan, Sainath |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa, Cisco |e verfasserin |4 aut | |
| 700 | 1 | |a Cabral, Howard J |e verfasserin |4 aut | |
| 700 | 1 | |a Burks, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a Meister, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Akpoviroro, Ogheneyoma |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Drozdowicz, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Litle, Virginia R |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Kei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lung cancer |d 1999 |g 23(2022), 2 vom: 25. März, Seite e165-e170 |w (DE-627)NLM143155229 |x 1938-0690 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g day:25 |g month:03 |g pages:e165-e170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cllc.2021.07.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 2 |b 25 |c 03 |h e165-e170 | ||